Ieq Capital LLC Purchases Shares of 33,123 Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Ieq Capital LLC has invested approximately $266,000 in Aurinia Pharmaceuticals, acquiring 33,123 shares of the company.
• Several institutional investors have also increased their stakes in Aurinia Pharmaceuticals, with GAMMA Investing LLC's stake growing by 56.1% in the same quarter.
• Aurinia Pharmaceuticals has received an "outperform" rating from Royal Bank Of Canada, with a revised price objective of $9.00 per share, reflecting positive market sentiment.

Ieq Capital LLC acquired a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 33,123 shares of the biotechnology company's stock, valued at approximately $266,000.

Other hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Aurinia Pharmaceuticals in the fourth quarter worth $27,000. Tower Research Capital LLC TRC boosted its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at $31,000. GAMMA Investing LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares during the period. Finally, USA Financial Formulas acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at $50,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, Director Kevin Tang acquired 200,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares in the company, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have bought 1,300,000 shares of company stock worth $13,590,000 in the last quarter. 12.20% of the stock is owned by insiders.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ AUPH traded down $0.04 during midday trading on Friday, reaching $12.74. 1,369,249 shares of the company traded hands, compared to its average volume of 1,528,409. Aurinia Pharmaceuticals Inc has a 52 week low of $6.55 and a 52 week high of $12.87. The stock has a 50-day moving average price of $10.76 and a 200 day moving average price of $8.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 29.63 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AUPH shares. Royal Bank Of Canada boosted their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reissued a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $12.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.